- Summit Therapeutics said it had dosed the first patient in the third phase of a clinical trial of an antibiotic to treat C.difficile infection.

The treatment, ridinilazole, had achieved statistical superiority over the standard of care, vancomycin, in the phase-two clinical trial.

'With positive results, we believe ridinilazole could be positioned as the drug of choice in the front-line treatment of C.difficile infection, which potentially provides patients with sustained cures and hospitals with compelling cost savings,' chief executive Glyn Edwards said.

At 1:10pm: [LON:SUMM] Summit Therapeutics PLC share price was +0.5p at 23.5p

Story provided by